Neurology® Podcast

Dr. Jeff Ratliff talks with Drs. Michael A. Van Es and Eva de Boer about the current diagnostic criteria for PLS, the role of genetic testing, and the clinical implications for patient management.  Read the related article in Neurology®.  Read the additional related article mentioned in this episode. Disclosures can be found at Neurology.org. 

Dr. BJ Hicks talks with Drs. Birgitte Hede Ebbesen and Boris Modrau about the study's methodology, findings, and implications for clinical practice, emphasizing the need for better awareness and support for TIA patients. Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

Dive into a fascinating discussion about the APOE4 genotype and its role in cognitive decline linked to Alzheimer's disease. The conversation highlights how increased Aβ deposition may exacerbate memory issues for APOE4 carriers. Gender differences in cognitive performance are uncovered, revealing unique patterns between males and females. There's emphasis on the importance of monitoring memory changes for early detection of impairment, and innovative trajectory modeling could enhance treatment decisions. Tune in for insights on risk factors and cognitive assessments!

Dr. Halley Alexander talks with Dr. Juan Luis Alcala-Zermeno about the outcomes of epilepsy surgery, specifically for patients with tonic-clonic seizures.  Read the related article in Epilepsia.  Read the additional related article in Epilepsia.  Listen to the previous podcast episode mentioned in this episode.  Disclosures can be found at Neurology.org.   

The August 2025 recall spotlights four previously released episodes on topics related to dementia diagnosis. The episode begins with Dr. Amy Brodtmann discussing the complexities of diagnosing frontotemporal dementia in clinical practice. Next, Dr. Joseph Therriault delves into the use of plasma biomarkers in diagnosing Alzheimer disease. In the third episode, Dr. Trey Bateman discusses the growing significance of blood-based biomarkers in Alzheimer disease. The episode concludes with Dr. Gregg Day discussing the clinical implications of using plasma biomarkers in real-world patient care. Podcast links:  Frontotemporal Dementia Differential Diagnosis in Clinical Practice Diagnosis of Alzheimer Disease Using Plasma Biomarkers Understanding Blood-Based Biomarkers in Alzheimer Disease Diagnostic Performance of Plasma Biomarkers in the Outpatient Memory Clinic Article links:  Frontotemporal Dementia Differential Diagnosis in Clinical Practice Diagnosis of Alzheimer’s Disease Using Plasma Biomarkers Adjusted to Clinical Probability Diagnostic Performance of Plasma p-tau217 and Aβ42/40 Biomarkers in the Outpatient Memory Clinic Disclosures can be found at Neurology.org. 

Dr. Kathryn Krulisky talks with Dr. Jordan Garris about educational gaps in understanding FND, the impact of stigma on patient care, and the importance of empathy in medical training.  Read the related article in Neurology® Education.  Disclosures can be found at Neurology.org.   

Dr. Daniel Blockmans, an internist from the University Hospital Gassisbury and an expert on giant cell arteritis, discusses groundbreaking findings on upadacitinib as a treatment alternative. He addresses the limitations of traditional glucocorticoid therapies and shares results from a Phase 3 trial showing upadacitinib's potential for sustained remission. The conversation also touches upon the safety profile, comparing it with tocilizumab and noting the importance of monitoring for opportunistic infections. Insights into differing treatment guidelines across regions add depth to the discourse.

Dr. Daniel Weintraub, a geriatric psychiatrist from the University of Pennsylvania, shares invaluable insights on cognitive concerns in Parkinson's disease. He highlights crucial predictors of dementia risk and reassures that many patients maintain good cognition for years. The discussion includes the importance of early screening for non-motor symptoms and the advancements in neuropsychological assessments. Treatment strategies are also explored, featuring cholinesterase inhibitors and the benefits of a comprehensive care approach.

Dr. James Ernest Siegler, a stroke and vascular neurologist, discusses the intricate challenges in treating embolic stroke of undetermined source (ESUS). He emphasizes the value of personalized treatment strategies, advocating for thorough evaluations to uncover hidden stroke mechanisms. The conversation highlights a critical study comparing antiplatelet agents and anticoagulants, suggesting that traditional approaches may need reevaluation. Comprehensive diagnostics and tailored management plans are essential to address the risks and benefits for diverse patient populations.

Dr. Trey Bateman talks with Dr. Gregg Day about the study design, findings, and clinical implications of using plasma biomarkers in real-world patient care.  Read the related article in Alzheimer's & Dementia.  Disclosures can be found at Neurology.org.